Supporting evidence
Semaglutide × Cardiovascular events
- Authoritative support
- 4
- Available studies
- 4
- Unavailable support
- 0
Available supporting studies
Study 1 · Included
Oral semaglutide may improve cardiovascular event prevention in type 2 diabetes.
Rct
- Comparison
- Participants receiving oral semaglutide for primary prevention of cardiovascular events. · Participants receiving standard care for diabetes management.
- Duration / follow-up
- 4 weeks
Study 2 · Included
Semaglutide improves cardiovascular outcomes in high-risk patients
Rct
- Comparison
- Patients with type 2 diabetes and high risk chronic kidney disease receiving semaglutide. · Patients with type 2 diabetes and high risk chronic kidney disease receiving placebo.
- Duration / follow-up
- 4 weeks
Relevant effects
Absolute change
42 · 0.029
Absolute change
52 · 0.01
Study 3 · Included
Semaglutide is safe for dialysis patients with type 2 diabetes
Rct
- Comparison
- Participants randomized to semaglutide who remained on treatment after dialysis initiation. · Participants randomized to placebo who remained on treatment after dialysis initiation.
- Duration / follow-up
- 5164 weeks
Study 4 · Included
Semaglutide may reduce cardiovascular events in non-diabetic patients.
Rct
- Comparison
- Participants received weekly injectable semaglutide 2.4 mg. · Participants received matching placebo.
- Duration / follow-up
- 13 weeks
Relevant effect
Percent change
20